At a glance
ClinicalIndex Comparison RecordN/ACompleted· 265 enrolled
Drug / intervention
Von Willebrand Factordrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Type 3 Von Willebrand International Registries Inhibitor Prospective Study
In Brief
An observational study evaluating Von Willebrand Factor for Type 3 Von Willebrand's Disease. Completed, enrolled 265 participants across 25 sites in 10 countries.
Detailed Summary
International Registries and Prospective Study on Type 3 Von Willebrand's Disease (VWD3), aimed to assess number, types and risk factors for bleeding and the efficacy and safety of plasma-derived and/or recombinant Von Willebrand Factor (VWF) concentrates used to treat VWD patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 3 Von Willebrand's Disease
CountriesFinland, France, Germany, Hungary, Iran, Italy, Netherlands, Spain, Sweden, United Kingdom
CollaboratorsSintesi Research Srl
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedJun 2015
Primary CompletionMar 2023
Study CompletionApr 2023
TodayJul 2026
First PostedJun 2, 2015
Enrollment StartNov 5, 2012
Primary CompletionMar 28, 2023
Study CompletionApr 17, 2023
TodayJul 2, 2026
Enrollment to primary: 10.4 yearsPosted 11.1 years ago
Interventions
Von Willebrand Factordrug
Replacement therapy with plasma-derived and/or recombinant VWF concentrates on-demand or under prophylaxis therapeutic scheme.